Top Cited Articles

We are delighted to share the 2019 impact factor for the Journal for ImmunoTherapy of Cancer of 10.252 (Journal Citation Reports, Clarivate Analytics), which ranked 16/244 in the Oncology category and 10/158 in the Immunology category.

The quality and impact of our journals are dependent on many different measures. We’ve provided here some of those metrics for Journal for ImmunoTherapy of Cancer, to reflect the latest 2020 data, that remain important to our authors. We’ve also listed our top most cited articles from each of the last two years, free to read.

2020

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
MARCH 2020 10.1136/jitc-2019-000337

Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer
FEBRUARY 2020 10.1136/jitc-2019-000110

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
MARCH 2020 10.1136/jitc-2019-000147

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
MAY 2020 10.1136/jitc-2020-000930

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
APRIL 2020 10.1136/jitc-2020-000878

Phase 2 study of pembrolizumab in patients with advanced rare cancers
MARCH 2020 10.1136/jitc-2019-000347

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
MARCH 2020 10.1136/jitc-2020-000530

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
FEBRUARY 2020 10.1136/jitc-2019-000433

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
JULY 2020 10.1136/jitc-2020-000891

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
JANUARY 2020 10.1136/jitc-2019-000376

2019

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
FEBRUARY 2019 10.1186/s40425-019-0527-y

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
APRIL 2019 10.1186/s40425-019-0585-1

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
APRIL 2019 10.1186/s40425-019-0577-1

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
JANUARY 2019 10.1186/s40425-018-0478-8

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
MAY 2019 10.1186/s40425-019-0617-x

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
JULY 2019 10.1186/s40425-019-0662-5

Exploring the emerging role of the microbiome in cancer immunotherapy
APRIL 2019 10.1186/s40425-019-0574-4

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
JULY 2019 10.1186/s40425-019-0659-0

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
JUNE 2019 10.1186/s40425-019-0623-z

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
APRIL 2019 10.1186/s40425-019-0579-z

Journal Metrics:

Speed
Days to first decision: 44
Days from acceptance to publication: 21

Impact
2 year Impact Factor (JCR): 9.913
SciMago Journal Rank (SJR): 4.194
Eigenfactor: 0.01603
Citescore: 8.6

Reach
Altmetric score: 5,976